cancer drug prices are rising faster than the prices in other sectors of health care and that the high cost of the drugs is not justified due to their limited efficacy. The results, according to the study, suggest that current pricing models are not rational, but are a reflection of what the market will bear. http://www.ascopost.com/ViewNews.aspx?nid=25660